1234402-77-7

1234402-77-7 structure

Name: CpG ODN 10101
Chemical Name: CpG ODN 10101
CAS Number: 1234402-77-7
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Anti-infection HCV
Create Date: 2023-03-10 19:52:02
Modify Date: 2024-04-05 20:20:13
CpG ODN 10101, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist. CpG ODN 10101 is a potent inducer of cytokine/chemokine expression ex vivo when used in combination with HH2(VQLRIRVAVIRA-NH2). CpG ODN 10101 induces IFN- secretion from dendritic cells (DCs) and stimulates B-cells.CpG ODN 10101 has antiviral and immunomodulatory properties that can influence chronic infection with HCV[1][2].

Name	CpG ODN 10101

Description	CpG ODN 10101, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist. CpG ODN 10101 is a potent inducer of cytokine/chemokine expression ex vivo when used in combination with HH2(VQLRIRVAVIRA-NH2). CpG ODN 10101 induces IFN- secretion from dendritic cells (DCs) and stimulates B-cells.CpG ODN 10101 has antiviral and immunomodulatory properties that can influence chronic infection with HCV[1][2].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Toll-like Receptor (TLR) Signaling Pathways >> Anti-infection >> HCV Research Areas >> Infection Research Areas >> Inflammation/Immunology
Target	TLR9
References	[1]. Jason Kindrachuk, et al. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine. 2009 Jul 23;27(34):4662-71. [2]. John G McHutchison, et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology. 2007 Nov;46(5):1341-9.

No Any Chemical & Physical Properties